Welcome!

News Feed Item

Spinal Cord Injury Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Cord Injury Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280945/Spinal-Cord-Injury-Global-Clinical-Trials-Review-H2-2014.html

Spinal Cord Injury Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Cord Injury Global Clinical Trials Review, H2, 2014" provides data on the Spinal Cord Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Cord Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Cord Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Cord Injury 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Cord Injury 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Spinal Cord Injury Therapeutics Clinical Trials 31
Prominent Drugs 33
Latest Clinical Trials News on Spinal Cord Injury 34
May 19, 2014: StemCells Provides Update on Its Phase I/II Study in Spinal Cord Injury 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Pfizer Inc. 35
Clinical Trial Overview of Pfizer Inc. 35
Acorda Therapeutics, Inc. 36
Clinical Trial Overview of Acorda Therapeutics, Inc. 36
Allergan, Inc. 37
Clinical Trial Overview of Allergan, Inc. 37
Stem Cell Sciences UK Ltd 38
Clinical Trial Overview of Stem Cell Sciences UK Ltd 38
Neuralstem, Inc. 39
Clinical Trial Overview of Neuralstem, Inc. 39
BioAxone BioSciences Inc. 40
Clinical Trial Overview of BioAxone BioSciences Inc. 40
AOSpine International 41
Clinical Trial Overview of AOSpine International 41
K-Stemcell Co., Ltd. 42
Clinical Trial Overview of K-Stemcell Co., Ltd. 42
Daiichi Sankyo Company, Limited 43
Clinical Trial Overview of Daiichi Sankyo Company, Limited 43
Bayer AG 44
Clinical Trial Overview of Bayer AG 44
Clinical Trial Overview of Top Institutes / Government 45
U.S. Department of Veterans Affairs 45
Clinical Trial Overview of U.S. Department of Veterans Affairs 45
University of Miami 48
Clinical Trial Overview of University of Miami 48
University of Washington 49
Clinical Trial Overview of University of Washington 49
National Institute of Neurological Disorders and Stroke 50
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 50
University of British Columbia 51
Clinical Trial Overview of University of British Columbia 51
Eunice Kennedy Shriver National Institute of Child Health and Human Development 52
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 52
China Spinal Cord Injury Network 53
Clinical Trial Overview of China Spinal Cord Injury Network 53
National Taiwan University Hospital 54
Clinical Trial Overview of National Taiwan University Hospital 54
James J. Peters Veterans Affairs Medical Center 55
Clinical Trial Overview of James J. Peters Veterans Affairs Medical Center 55
University of California, Irvine 56
Clinical Trial Overview of University of California, Irvine 56
Five Key Clinical Profiles 57
Appendix 104
Abbreviations 104
Definitions 104
Research Methodology 105
Secondary Research 105
About GlobalData 106
Contact Us 106
Disclaimer 106
Source 106

List of Tables

Spinal Cord Injury Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Cord Injury Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Cord Injury Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Spinal Cord Injury Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Cord Injury Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Cord Injury Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Cord Injury Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Cord Injury Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Cord Injury Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Spinal Cord Injury Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Spinal Cord Injury Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Spinal Cord Injury Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Spinal Cord Injury Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 29
Spinal Cord Injury Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Spinal Cord Injury Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Spinal Cord Injury Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 35
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Acorda Therapeutics, Inc., 2014* 36
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2014* 37
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Stem Cell Sciences UK Ltd, 2014* 38
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Neuralstem, Inc., 2014* 39
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by BioAxone BioSciences Inc., 2014* 40
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by AOSpine International, 2014* 41
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by K-Stemcell Co., Ltd., 2014* 42
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 43
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 44
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 45
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Miami, 2014* 48
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 49
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 50
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of British Columbia, 2014* 51
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 52
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by China Spinal Cord Injury Network, 2014* 53
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 54
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by James J. Peters Veterans Affairs Medical Center, 2014* 55
Spinal Cord Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2014* 56

List of Figures

Spinal Cord Injury Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Cord Injury Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Cord Injury Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Spinal Cord Injury Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Cord Injury Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Spinal Cord Injury Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Spinal Cord Injury Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Cord Injury Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Cord Injury to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Cord Injury Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Cord Injury Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Cord Injury Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Cord Injury Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Cord Injury Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Spinal Cord Injury Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 29
Spinal Cord Injury Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Spinal Cord Injury Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Spinal Cord Injury Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
GlobalData Methodology 105

To order this report: Spinal Cord Injury Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280945/Spinal-Cord-Injury-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
In the first article of this three-part series on hybrid cloud security, we discussed the Shared Responsibility Model and examined how the most common attack strategies persist, are amplified, or are mitigated as assets move from data centers to the cloud. Today, we’ll look at some of the unique security challenges that are introduced by public cloud environments. While cloud computing delivers many operational, cost-saving and security benefits, it takes place in a public, shared and on-demand ...
In his session at @ThingsExpo, Sudarshan Krishnamurthi, a Senior Manager, Business Strategy, at Cisco Systems, will discuss how IT and operational technology (OT) work together, as opposed to being in separate siloes as once was traditional. Attendees will learn how to fully leverage the power of IoT in their organization by bringing the two sides together and bridging the communication gap. He will also look at what good leadership must entail in order to accomplish this, and how IT managers ca...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
SYS-CON Events announced today that Outlyer, a monitoring service for DevOps and operations teams, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outlyer is a monitoring service for DevOps and Operations teams running Cloud, SaaS, Microservices and IoT deployments. Designed for today's dynamic environments that need beyond cloud-scale monitoring, we make monitoring effortless so you...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at @ThingsExpo, Steve Wilkes, CTO and founder of Striim, will delve into four enterprise-scale, business-critical case studies where streaming analytics serves as the key to enabling real-time data integration and right-time insights in hybrid cloud, IoT, and fog computing environments. As part of this discussion, he will also present a demo based on its partnership with Fujitsu, highlighting their technologies in a healthcare IoT use-case. The demo showcases the tracking of pati...
SYS-CON Events announced today that Cloud Academy will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloud Academy is the industry’s most innovative, vendor-neutral cloud technology training platform. Cloud Academy provides continuous learning solutions for individuals and enterprise teams for Amazon Web Services, Microsoft Azure, Google Cloud Platform, and the most popular cloud computing technologies. Ge...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, Cloud Expo and @ThingsExpo are two of the most important technology events of the year. Since its launch over eight years ago, Cloud Expo and @ThingsExpo have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, I provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading the...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.